Search

everythinglearnresearchcommunity

for

Search:↓

This randomized controlled trial compared the efficacy of baricitinib and methotrexate in treating severe alopecia areata in 84 patients. Patients were divided into two groups, with group A receiving baricitinib and group B receiving methotrexate. Over 6 months, group A showed significantly greater improvement in the Severity of Alopecia Tool (SALT) scores compared to group B. At month 6, 57.1% of patients in group A achieved a complete response (SALT90), while none in group B did. The study concludes that baricitinib is superior to methotrexate for treating severe alopecia areata, suggesting it as an excellent choice for patients with extensive disease, though further research is needed to evaluate long-term efficacy.

A randomized controlled trial conducted at Bangabandhu Sheikh Mujib Medical University compared the efficacy of oral baricitinib and methotrexate in treating severe alopecia areata in 84 patients. Group A received baricitinib, while Group B received methotrexate. After 6 months, baricitinib significantly outperformed methotrexate, with a greater reduction in the Severity of Alopecia Tool (SALT) score and higher rates of excellent (SALT75) and complete (SALT90) responses. Specifically, 57.1% of patients in Group A achieved a complete response compared to none in Group B. The study concludes that baricitinib is a superior treatment option for severe alopecia areata, though further research is needed to evaluate its long-term efficacy.